<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eyal Grunebaum, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald B Kohn, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer M Puck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Adenosine deaminase (ADA) deficiency (MIM #102700) was the first immunodeficiency in which the specific molecular defect was identified. This autosomal-recessive genetic disorder typically leads to a severe combined immunodeficiency (SCID)  (<a class="graphic graphic_table graphicRef139920" href="/z/d/graphic/139920.html" rel="external">table 1</a>) with dysfunction of T, B, and natural killer (NK) cells (T-B-NK- SCID) that presents in the first few months of life. However, there are also a few patients with a later onset and relatively milder disease. The wide spectrum of the ADA deficiency phenotype is largely related to the variability in genetic mutations and the amount of residual ADA enzyme activity.</p><p>The pathogenesis, clinical manifestations, and diagnosis of ADA deficiency are presented in this topic review. The treatment of ADA deficiency is discussed separately, as is the related combined immunodeficiency disorder, purine nucleoside phosphorylase deficiency. (See  <a class="medical medical_review" href="/z/d/html/3910.html" rel="external">"Adenosine deaminase deficiency: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/3943.html" rel="external">"Purine nucleoside phosphorylase deficiency"</a>.)</p><p>An overview of SCID and detailed discussions on other SCID syndromes and combined immunodeficiencies are also covered separately  (<a class="graphic graphic_table graphicRef139920" href="/z/d/graphic/139920.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview"</a> and  <a class="medical medical_review" href="/z/d/html/3912.html" rel="external">"Severe combined immunodeficiency (SCID): Specific defects"</a> and  <a class="medical medical_review" href="/z/d/html/3935.html" rel="external">"Combined immunodeficiencies: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/141326.html" rel="external">"Combined immunodeficiencies: Specific defects"</a>.)</p><p>ADA2 is another enzyme that has partial structural homology with ADA1 and is able to convert adenosine and 2-deoxyadenosine, albeit at a much lower affinity. Autosomal-recessive defects in <em>ADA2</em> cause autoinflammatory disease and autoimmunity and are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults", section on 'Etiology'</a> and  <a class="medical medical_review" href="/z/d/html/6213.html" rel="external">"Ischemic stroke in children and young adults: Epidemiology, etiology, and risk factors"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>ADA deficiency has an overall incidence of 1 in 200,000 livebirths, with a much higher rate among some populations such as the Somali [<a href="#rid1">1</a>] and Amish/Mennonites [<a href="#rid2">2</a>]. ADA deficiency accounts for approximately one-third of all cases of autosomal-recessive severe combined immunodeficiency (SCID) and approximately 10 to 15 percent of all cases of SCID [<a href="#rid3">3-5</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>ADA is a ubiquitous enzyme found in all cells, including red and white blood cells, and in the serum. It catalyzes the deamination of adenosine and deoxyadenosine to inosine and deoxyinosine, which are converted to waste products and excreted. ADA deficiency is an autosomal-recessive disorder caused by pathogenic variants in the <em>ADA1 </em>gene at 20q13.11 (MIM *608958) [<a href="#rid6">6-9</a>]. As little as 3 percent of residual enzyme activity can maintain nearly functional immunity into adulthood. Thus, a few patients have maintained normal immune function until immunologic decompensation occurs in adulthood and infectious complications bring attention to the diagnosis. There are also some people with "partial" ADA deficiency, who have enzyme activity ranging from 5 to 80 percent of normal but who otherwise have normal immunologic features [<a href="#rid10">10</a>].</p><p>In the absence of functional ADA, there is systemic accumulation of adenosine and deoxyadenosine. The replicative activity of the cell dictates the level of sensitivity to these toxic metabolites. Adenosine and deoxyadenosine are also converted to 5'-deoxyadenosine triphosphate (dATP), which inhibits ribonucleotide reductase and prevents de novo synthesis of nucleotides and deoxynucleotides. There is a decrease in deoxyribonucleic acid (DNA) synthesis in replicating cells because of the depletion of deoxynucleotides. In addition, deoxyadenosine irreversibly binds to and inhibits S-adenosylhomocysteine hydrolase, which also contributes to abnormal DNA synthesis [<a href="#rid11">11,12</a>].</p><p>ADA concentration is highest in the thymus, which probably accounts for the dependence of T cell development and maturation upon this enzyme. The absence of ADA and/or the presence of purine toxic metabolites may therefore be responsible for the early involution and dysplasia of the thymus observed with this disorder.</p><p>Several in vitro and animal models have attempted to unravel the mechanisms by which ADA deficiency causes this immune aberration. The in vitro models have relied upon two competitive inhibitors of ADA, erythro-9-(2hydroxy-3nonyl) adenine (EHNA) and 2'deoxycoformycin (dCF). In vitro, both compounds suppress lymphocyte mitogenic and antigenic responses that are partially reversed by exogenous ADA [<a href="#rid13">13</a>]. In addition, disease modeling with patient-derived induced pluripotent stem cells has shown that ADA deficiency impairs neutrophil development and differentiation [<a href="#rid14">14</a>].</p><p>The effect of ADA inhibition was studied in a chimeric human/mouse fetal thymic organ culture that mimicked an in vivo environment in which toxic metabolites accumulated [<a href="#rid15">15</a>]. Thymocyte expansion and differentiation were impaired by ADA inhibition. The decrease in mature thymocytes was primarily due to apoptosis that was associated with accumulation of intracellular dATP. Inhibition of adenosine kinase and deoxycytidine kinase prevented accumulation of dATP and restored thymocyte proliferation and differentiation.</p><p>Initial attempts to create animal models of ADA deficiency failed since mice lacking ADA died perinatally from hepatocellular necrosis, although their lymphoid tissue was largely not affected [<a href="#rid16">16</a>]. Subsequently, an ADA-deficient mouse model with a combined immunodeficiency and many of the other features seen in humans was created using a two-stage genetic engineering strategy [<a href="#rid17">17</a>]. These ADA-deficient mice were rescued from perinatal lethality by restoring Ada expression to trophoblast cells. In another study of this mouse model, T cell apoptosis was abundant in thymi, but no increase in apoptosis was detected in the spleen and lymph nodes, suggesting that the defect is specific to developing thymocytes [<a href="#rid18">18</a>]. In contrast, human studies in five patients with ADA deficiency showed that in vitro peripheral blood lymphocyte treatment with ADA metabolites induced a three- to fourfold higher proportion of<sup> </sup>apoptotic cells in ADA<sup>–/–</sup> T cells compared with<sup> </sup>normal cells, suggesting that mature ADA-deficient T cells are also prone to increased apoptosis [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H2652394081"><span class="h2">Clinical spectrum</span><span class="headingEndMark"> — </span>The clinical spectrum of ADA deficiency has broadened over time as patients with atypical or milder forms due to the variability of specific genetic mutations have been identified. In addition, the ubiquitous expression of ADA and the important role that ADA substrates and products have in many biologic processes result in diverse nonimmune abnormalities.</p><p class="headingAnchor" id="H2625952294"><span class="h2">Age at presentation</span><span class="headingEndMark"> — </span>Approximately 90 percent of patients with ADA deficiency have a classic severe combined immunodeficiency (SCID) phenotype in which the disease presents in the first months of life. Most of the remainder have a "delayed" (6 to 24 months) or "late" (four years to adulthood) onset form [<a href="#rid20">20,21</a>]. Such patients may initially have variable numbers of circulating lymphocytes and some humoral immunity that quickly wanes.</p><p class="headingAnchor" id="H696207040"><span class="h2">Immunodeficiency</span><span class="headingEndMark"> — </span>Most patients with ADA deficiency have SCID, but the degree of the immune defect can vary widely. (See <a class="local">'Pathogenesis'</a> above.)</p><p class="headingAnchor" id="H5"><span class="h3">Severe combined immunodeficiency phenotype</span><span class="headingEndMark"> — </span>Most patients with ADA deficiency present with life-threatening infections, chronic persistent diarrhea, and failure to thrive in the first months of life. This phenotype is almost indistinguishable from that of patients with SCID due to other etiologies. The disease in these early-onset patients is invariably fatal in the first year or two of life without treatment. Maternal T cell engraftment may occur and can impede the diagnosis [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview", section on 'Detection of maternal T cell engraftment'</a>.)</p><p>Some neonates present with prolonged hyperbilirubinemia and hepatitis [<a href="#rid23">23</a>]. In others, a severe neonatal Omenn syndrome is the initial manifestation [<a href="#rid24">24</a>]. This is characterized by a maculopapular rash that becomes desquamative, acute necrotizing hepatitis with jaundice, interstitial pneumonitis, and massive diarrhea.</p><p>Initial infections may affect the lungs, gastrointestinal tract, and skin [<a href="#rid25">25</a>], with acute and recurrent infections caused by bacterial, protozoal, fungal, and viral agents. The most frequent organisms and sites of infection are:</p><p class="bulletIndent1"><span class="glyph">●</span><em>Pneumocystis jirovecii</em> (<em>carinii</em>) pneumonia</p><p class="bulletIndent1"><span class="glyph">●</span>Oral, esophageal, and intestinal candidiasis</p><p class="bulletIndent1"><span class="glyph">●</span>Candidal dermatitis of the diaper region</p><p class="bulletIndent1"><span class="glyph">●</span>Herpes virus infections, including cytomegalovirus (CMV), Epstein-Barr virus (EBV), and varicella-zoster virus (VZV)</p><p class="bulletIndent1"><span class="glyph">●</span>Parainfluenza and enterovirus infections</p><p></p><p>Immunization with live vaccines, such as Bacille Calmette-Guérin (BCG), can lead to disseminated infection and sometimes death [<a href="#rid26">26</a>]. Similarly, persistent diarrhea often develops after rotavirus vaccination in patients with ADA deficiency [<a href="#rid27">27</a>].</p><p>Transfusion of nonirradiated blood will invariably result in a fatal graft-versus-host reaction. (See  <a class="medical medical_review" href="/z/d/html/7928.html" rel="external">"Transfusion-associated graft-versus-host disease"</a>.)</p><p>The physical examination in patients with a SCID phenotype frequently reveals small tonsils and the absence of palpable lymph nodes. Additional findings may include hepatosplenomegaly and possibly other features of Omenn syndrome [<a href="#rid24">24</a>]. Prominence of the costochondral junctions similar to rachitic rosary is sometimes observed. Skin findings of dermatofibrosarcoma protuberans (DFSP)  (<a class="graphic graphic_picture graphicRef135226" href="/z/d/graphic/135226.html" rel="external">picture 1</a>), atrophic plaques, or protuberant lesions may be present.</p><p class="headingAnchor" id="H7"><span class="h3">Milder immunologic phenotypes</span><span class="headingEndMark"> — </span>Patients who present later in life can have symptoms and signs similar to those presenting in childhood. However, milder forms of the disease have also been identified. The severity depends upon the extent of the quantitative and qualitative ADA deficiency. (See <a class="local">'Pathogenesis'</a> above.)</p><p>The following observations indicate that ADA deficiency can manifest later in childhood into adulthood and partial ADA deficiency can lead over time to a deterioration of immune function. Thus, ADA deficiency should be considered in the differential diagnosis in patients of any age who present with unexplained lymphopenia and immune deficiency.</p><p class="bulletIndent1"><span class="glyph">●</span>Four children with partial ADA deficiency were described in one case series [<a href="#rid10">10</a>]. These children lacked ADA in red blood cells but retained variable ADA activity in lymphoid cells. Three of these patients had heat-labile ADA mutations that are seen with greater prevalence in the Caribbean and may have a selective advantage with regard to malaria and <em>Babesia</em> infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A child with a partial ADA deficiency was described in whom immune functions deteriorated over time [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 12-year-old child was diagnosed with ADA deficiency after presenting with Heck disease (human papilloma virus-induced focal epithelial hyperplasia of the oral mucosa) [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one report, an adult form of ADA deficiency was described in 34- and 35-year-old sisters who had been lymphopenic from age 17 and 20 years, respectively [<a href="#rid20">20</a>]. Both had severe CD4-positive lymphopenia, with recurrent bacterial, fungal, and viral infections and chronic lung disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another report, a 39-year-old woman was reported with a combined immunodeficiency and lymphopenia [<a href="#rid30">30</a>]. She succumbed to a viral leukoencephalopathy at the age of 40 years. A 28-year-old male described in the same report was diagnosed after his niece died of a SCID [<a href="#rid30">30</a>]. He was healthy and had normal immune function. Both the 28-year-old male and the 39-year-old woman lacked red blood cell ADA activity but had only modestly elevated deoxyadenosine nucleotides [<a href="#rid30">30</a>].</p><p></p><p class="headingAnchor" id="H3679747499"><span class="h2">Autoimmunity</span><span class="headingEndMark"> — </span>Diverse autoimmune abnormalities have been reported among patients with ADA deficiency, particularly in those with milder forms of the disease. Manifestations include autoimmune hypothyroidism, diabetes mellitus, hemolytic anemia, and immune thrombocytopenia. The immune dysregulation has been attributed to impaired function of regulatory T cells [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/16362.html" rel="external">"Autoimmunity in patients with inborn errors of immunity/primary immunodeficiency"</a>.)</p><p class="headingAnchor" id="H297665167"><span class="h2">Malignancy</span><span class="headingEndMark"> — </span>The two most common malignancies reported in patients with ADA deficiency are lymphoma and DFSP.</p><p class="headingAnchor" id="H8"><span class="h3">Lymphoma</span><span class="headingEndMark"> — </span>Lymphoma most commonly occurs in patients with ADA deficiency treated with enzyme replacement therapy for extensive periods. It is often EBV induced, although EBV-negative lymphoma has also been described [<a href="#rid32">32</a>]. One review identified nine patients with ADA deficiency (out of an unknown total) who developed lymphoma, with 89 percent mortality [<a href="#rid33">33</a>]. The only surviving patient, who was treated with three cycles of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> followed by six cycles of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, was in remission for more than 12 years until recurrence of disseminated EBV-negative lymphoma [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/95906.html" rel="external">"Malignancy in inborn errors of immunity"</a>.)</p><p class="headingAnchor" id="H27972002"><span class="h3">Dermatofibrosarcoma protuberans</span><span class="headingEndMark"> — </span>DFSP is a rare malignant skin tumor associated with a t(17;22)(q22;q13) translocation that results in a type 1 collagen alpha-1 chain (<em>COL1A1</em>) platelet-derived growth factor beta (<em>PDGFB</em>) fusion gene  (<a class="graphic graphic_picture graphicRef135226" href="/z/d/graphic/135226.html" rel="external">picture 1</a>). A high incidence of DFSP, usually with multicentric involvement, is seen in patients with ADA-SCID [<a href="#rid35">35</a>]. Since this malignancy was first reported in association with ADA-SCID in 2011, there have been no reports of progression of the lesions to dissemination, and it remains uncertain whether excision or careful serial observation is best. (See  <a class="medical medical_review" href="/z/d/html/7747.html" rel="external">"Dermatofibrosarcoma protuberans: Epidemiology, pathogenesis, clinical presentation, diagnosis, and staging"</a>.)</p><p class="headingAnchor" id="H2137904133"><span class="h3">Somatic chromosomal abnormalities</span><span class="headingEndMark"> — </span>Somatic chromosome anomalies were identified in a patient with ADA deficiency found to have an asymptomatic large lipoid abdominal tumor [<a href="#rid36">36</a>] and another with myeloid abnormalities and trisomy 8 mosaicism [<a href="#rid37">37</a>]. The frequent chromosomal abnormalities may be related to impaired adenosine homeostasis.</p><p class="headingAnchor" id="H383688181"><span class="h2">Pulmonary abnormalities</span><span class="headingEndMark"> — </span>The primary pulmonary disorder seen in patients with ADA deficiency is pulmonary alveolar proteinosis (PAP). Asthma and bronchiectasis are seen in older patients.</p><p class="headingAnchor" id="H5254318"><span class="h3">Pulmonary alveolar proteinosis</span><span class="headingEndMark"> — </span>PAP is a rare disorder caused by accumulation of surfactant-derived components in the lungs that is seen with high frequency in infants with ADA deficiency [<a href="#rid38">38</a>]. It often presents with tachypnea, hypoxia, and hazy pulmonary infiltrates at the time of disease recognition, making distinction from infectious etiologies such as <em>P. jirovecii</em> pneumonia difficult. Studies in ADA-deficient mice suggest that impaired function of alveolar macrophages, important for the clearance of surfactant, causes PAP [<a href="#rid39">39,40</a>]. PAP is reversible with enzyme replacement therapy and hematopoietic cell transplantation (HCT). (See  <a class="medical medical_review" href="/z/d/html/3910.html" rel="external">"Adenosine deaminase deficiency: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H2059354946"><span class="h3">Asthma and bronchiectasis</span><span class="headingEndMark"> — </span>Older patients with ADA deficiency also frequently suffer from pulmonary abnormalities including asthma and bronchiectasis [<a href="#rid41">41</a>]. In one series, 7 out of 10 patients had abnormal baseline pulmonary function, and half had significant reversible airway obstruction [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H4290984475"><span class="h2">Neurologic abnormalities</span><span class="headingEndMark"> — </span>Neurologic abnormalities are frequently associated with ADA deficiency and include neurocognitive and learning deficits, behavioral problems, coordination and gait abnormalities, hypo- and hypertonia, sensorineural hearing loss, and seizures [<a href="#rid43">43-45</a>]. A retrospective study of the US Immunodeficiency Network (USIDNET) registry identified one or more of these neurologic conditions in 45 percent of 64 patients with ADA deficiency [<a href="#rid46">46</a>]. Many of these abnormalities are not reversed by treatment (enzyme replacement therapy or HCT). However, the absolute frequencies of neurologic complications in patients with ADA-SCID who are diagnosed and treated early without severe intervening infections have not been defined. (See  <a class="medical medical_review" href="/z/d/html/3910.html" rel="external">"Adenosine deaminase deficiency: Treatment and prognosis"</a>.)</p><p>In a study of 12 patients with ADA deficiency who survived HCT, six demonstrated significant neurologic abnormalities. The central nervous system (CNS) abnormalities were probably due to the metabolic abnormalities of ADA deficiency and not to complications of transplantation [<a href="#rid44">44</a>]. Brain magnetic resonance imaging (MRI) evaluation in patients with ADA deficiency revealed leukoencephalopathy, enlargement of ventricles, and subarachnoid spaces [<a href="#rid47">47</a>].</p><p>In a cohort study of 105 patients who underwent HCT for severe congenital immunodeficiencies, ADA-SCID was associated with a lower intelligence quotient (IQ) and higher rates of emotional and behavioral difficulties compared with the other SCID groups [<a href="#rid48">48</a>]. Bilateral sensorineural hearing loss was reported in 7 of 12 patients (58 percent) in another series who all had received HCT [<a href="#rid45">45</a>]. Hearing deficits may contribute to significantly reduced verbal and total IQ assessments [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H4033587360"><span class="h2">Kidney and urogenital abnormalities</span><span class="headingEndMark"> — </span>Hemolytic uremic syndrome with acute kidney injury was identified in an increasing number of children with ADA deficiency who had no evidence of infection with Shiga-toxigenic organisms [<a href="#rid49">49-51</a>]. Whether the kidney disease, which was not reported to reoccur, is related to effects of adenosine on endothelia, adenosine-mediated signaling abnormalities, or the previously described mesangial sclerosis [<a href="#rid52">52</a>] is still not known. A high prevalence of cryptorchidism was reported among males with ADA deficiency in a retrospective study [<a href="#rid53">53</a>]. The majority of patients had spontaneous pubertal development, although a few cases of precocious or delayed puberty were reported. No patients were found to have elevated follicle-stimulating hormone (FSH) levels. (See  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">LABORATORY, RADIOGRAPHIC, AND HISTOLOGIC FINDINGS</span><span class="headingEndMark"> — </span>Patients with ADA deficiency typically have severely reduced numbers of T, B, and natural killer (NK) cells [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Metabolic abnormalities</span><span class="headingEndMark"> — </span>In normal persons, levels of adenosine and other purine nucleosides and deoxynucleosides in the plasma and urine are extremely low or undetectable due to rapid equilibration across cell membranes and prompt metabolism.</p><p>With ADA deficiency, the normal metabolic routes for these compounds are unavailable. Thus, the levels of deoxyadenosine and deoxyadenosine triphosphate (dATP) rise sharply after birth since the "detoxification" by the in utero heterozygote levels of maternal ADA are no longer available, resulting in the following biochemical hallmarks of the disease:</p><p class="bulletIndent1"><span class="glyph">●</span>In red blood cells, there is a massive increase in adenosine, deoxyadenosine, and dATP concentrations and a decrease in adenosine triphosphate (ATP) values [<a href="#rid54">54,55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The plasma concentrations of adenosine and deoxyadenosine are variable but are usually elevated to between 0.5 and 10 mM, respectively [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the urine, adenosine levels are lower than deoxyadenosine, reflecting the more efficient reutilization of adenosine than deoxyadenosine by phosphorylation in the cells [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The activity of S-adenosylhomocysteine hydrolase in red blood cells is markedly decreased since this enzyme is inactivated by deoxyadenosine [<a href="#rid11">11</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Immune laboratory values</span><span class="headingEndMark"> — </span>In ADA-deficient severe combined immunodeficiency (SCID), the severe T cell deficiency is manifested by [<a href="#rid3">3,25,41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe lymphopenia, with low numbers of CD3+ and CD4+ T cells compared with age-matched controls</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poor in vitro lymphocyte mitogenic and antigenic responses</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absent mixed lymphocyte reactions (MLRs)</p><p></p><p>B and NK cells are typically also severely reduced in patients with ADA-SCID. However, some patients may retain NK cells and even B cells. B cell function is variable. Most patients are unable to mount specific antibody responses and have variable immunoglobulin deficiencies, including low or absent immunoglobulin A (IgA) or immunoglobulin M (IgM) levels and low total immunoglobulin G (IgG) or IgG subclasses, particularly IgG2. Several patients were found to have markedly increased serum immunoglobulin E (IgE) levels. Panhypogammaglobulinemia has also been observed.</p><p>Neutropenia occurs in the majority of patients [<a href="#rid57">57</a>]. Additional hematologic laboratory abnormalities may also include autoimmune hemolytic anemia, thrombocytopenia, and eosinophilia.</p><p class="headingAnchor" id="H13"><span class="h2">Radiographs</span><span class="headingEndMark"> — </span>The chest radiograph reveals the absence of a thymic shadow  (<a class="graphic graphic_diagnosticimage graphicRef119937" href="/z/d/graphic/119937.html" rel="external">image 1</a>). Radiographs also display flaring of the anterior ribs, pelvic dysplasia, and shortening of the transverse vertebral processes with flattening of their ends (platyspondyly) and thick growth arrest lines  (<a class="graphic graphic_diagnosticimage graphicRef135224" href="/z/d/graphic/135224.html" rel="external">image 2</a>) [<a href="#rid58">58</a>]. Other characteristic findings include squaring or spurring of the inferolateral margin of the scapula  (<a class="graphic graphic_diagnosticimage graphicRef119937" href="/z/d/graphic/119937.html" rel="external">image 1</a>); cupping of the anterior rib ends, best viewed by lateral imaging; and diffuse osteopenia of the bones [<a href="#rid59">59</a>]. The bone abnormalities seen in patients have been attributed to imbalance in receptor activator of nuclear factor kappa-B ligand (RANKL)/osteoprotegerin, which were also identified in ADA-deficient mice [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Histology</span><span class="headingEndMark"> — </span>Patients with ADA-SCID often have myeloid dysplasia and bone marrow hypocellularity [<a href="#rid61">61</a>]. Autopsy findings in eight patients with ADA deficiency demonstrated that thymus weights were 2 to 30 percent of expected [<a href="#rid62">62</a>]. Histologically, the thymus is dysplastic, with poor corticomedullary differentiation, small nests of undifferentiated epithelial cells, and absence of Hassall's corpuscles.</p><p class="headingAnchor" id="H15"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H1075405060"><span class="h2">When to suspect the diagnosis</span><span class="headingEndMark"> — </span>Infants can be detected on newborn screening (NBS) prior to onset of symptoms if the test is included on the panel. Children with ADA-deficient severe combined immunodeficiency (SCID) who are born in locales where testing for SCID is not included on the NBS panel most often present with typical signs and symptoms of SCID including failure to thrive, life-threatening infections, chronic mucocutaneous fungal infections, and/or opportunistic infections. Features that suggest ADA deficiency, but not most other forms of SCID, include earlier age of presentation with failure to thrive and noninfectious respiratory distress (often before four months of age), rib cage abnormalities, early neurologic abnormalities, and sensory-neural hearing loss. In late presenters, recurrent infection, opportunistic infections, and an unexplained lymphopenia may raise the suspicion of an unusual form of ADA deficiency. (See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview"</a> and <a class="local">'Severe combined immunodeficiency phenotype'</a> above and  <a class="medical medical_review" href="/z/d/html/16363.html" rel="external">"Newborn screening for inborn errors of immunity", section on 'Screening for SCID and other T cell defects'</a> and <a class="local">'Newborn screening'</a> below.)</p><p class="headingAnchor" id="H4293058729"><span class="h2">Newborn screening</span><span class="headingEndMark"> — </span>NBS via quantification of T cell receptor excision circles (TRECs) has proven an important way to diagnose ADA deficiency early in infancy, prior to the onset of severe infections [<a href="#rid41">41,63-65</a>]. TRECs are formed during the differentiation of T cells in the thymus. They serve as a marker for naïve T cells in the peripheral blood and can be enumerated using dried blood spots on NBS cards [<a href="#rid66">66</a>]. TRECs are low to absent in over 90 percent of patients with ADA-SCID. However, T cells and TRECs may still be present if measured in the first few days of life in newborns with ADA deficiency because there is some degree of in utero detoxification by maternal ADA. In addition, TREC assays may not detect delayed or late-onset ADA deficiency, due to sufficient residual levels of ADA in the newborn period. (See  <a class="medical medical_review" href="/z/d/html/16363.html" rel="external">"Newborn screening for inborn errors of immunity", section on 'Screening for SCID and other T cell defects'</a>.)</p><p>An alternative approach to NBS for ADA deficiency using tandem mass spectrometry can also correctly identify infants with residual ADA activity, although it has not been widely implemented [<a href="#rid67">67,68</a>]. This is particularly beneficial for situations of delayed- or late-onset ADA deficiency as these patients may have normal TREC levels at the time of NBS testing yet will already have elevated adenosine and deoxyadenosine that can be detected by tandem mass spectrometry [<a href="#rid69">69,70</a>].</p><p class="headingAnchor" id="H4057802509"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>The patient suspected of having SCID of any etiology requires the complete evaluation of specific humoral and cellular immunity. Studies include the measurement of immunoglobulin levels, absolute numbers and percentages of lymphocyte subsets (T, B, and natural killer [NK]), and assessment of T cell function. In this situation, T cell function is usually determined by in vitro measurement of responses to mitogens, such as phytohemagglutinin (PHA) and concanavalin A (ConA). The diagnostic evaluation for SCID is reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/3903.html" rel="external">"Laboratory evaluation of the immune system"</a>.)</p><p>ADA-SCID is suggested by finding severe pan lymphopenia with T cell deficiency, as expressed by lymphopenia with low numbers of CD3+ and CD4+ cells, poor in vitro lymphocyte mitogenic and antigenic responses, and absent mixed lymphocyte reactions (MLRs). Most patients also have marked reduction of B and NK cells (T-B-NK- SCID).</p><p>Other laboratory findings that assist in the diagnosis of ADA deficiency include the detection of nonhemolytic neutropenia [<a href="#rid57">57</a>], noninfectious mild-to-moderate hepatitis, and periodic acid-Schiff stain positive (PAS+) proteinaceous noninfectious alveolar lavage.</p><p class="headingAnchor" id="H359326045"><span class="h2">Tests specific for ADA deficiency</span><span class="headingEndMark"> — </span>The major diagnostic metabolic laboratory findings specific for ADA deficiency, which are also used to monitor treatment results, are the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Absent ADA levels in lysed erythrocytes from fresh blood samples or dried blood spots. This test is available at several commercial and research centers, while the remaining assays are only available at few specialized laboratories.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A marked increase in deoxyadenosine triphosphate (dATP) levels in erythrocyte lysates (with levels that vary by laboratory).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A significant decrease in ATP concentration in red blood cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absent or extremely low levels of s-adenosylhomocysteine hydrolase in red blood cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increase in 2'-deoxyadenosine in urine and plasma, as well as in dried blood spots.</p><p></p><p class="headingAnchor" id="H4100964488"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>The diagnosis is confirmed by identification of biallelic pathogenic variants in the <em>ADA1</em> gene.</p><p class="headingAnchor" id="H16"><span class="h2">Prenatal diagnosis</span><span class="headingEndMark"> — </span>Prenatal diagnosis can be made by mutational analysis or by evaluation of ADA activity in cultured fibroblasts from amniotic fluid [<a href="#rid13">13</a>] and from chorionic villus sampling [<a href="#rid71">71</a>]. Prenatal diagnosis via molecular genetic testing is an option for those families in which the mutations causing ADA deficiency have been identified [<a href="#rid72">72</a>]. Amniocentesis is indicated in any pregnancy that follows the birth of a child with ADA deficiency.</p><p class="headingAnchor" id="H17"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of ADA deficiency includes all other forms of autosomal-recessive severe combined immunodeficiency (SCID), complete DiGeorge syndrome, and purine nucleoside phosphorylase deficiency.</p><p class="bulletIndent1"><span class="glyph">●</span>Several clinical characteristics can help differentiate ADA deficiency from other forms of SCID. (See <a class="local">'When to suspect the diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/3912.html" rel="external">"Severe combined immunodeficiency (SCID): Specific defects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The lack of associated facial and structural anomalies can help distinguish between ADA deficiency and DiGeorge syndrome. (See  <a class="medical medical_review" href="/z/d/html/3905.html" rel="external">"DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of normal uric acid helps differentiate ADA deficiency from purine nucleoside phosphorylase deficiency. (See  <a class="medical medical_review" href="/z/d/html/3943.html" rel="external">"Purine nucleoside phosphorylase deficiency"</a>.)</p><p></p><p class="headingAnchor" id="H1636455976"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathogenesis </strong>– Adenosine deaminase (ADA) deficiency (MIM #102700) is a rare, autosomal-recessive genetic disorder caused by pathogenic variants in the <em>ADA1</em> gene at 20q13.11 (MIM *608958). In the absence of functional ADA, there is an intracellular accumulation of adenosine and deoxyadenosine. These products are toxic to lymphocytes and lead to dysfunction of T, B, and natural killer (NK) cells that can range in severity from T-B-NK- severe combined immunodeficiency (SCID) to milder phenotypes. The wide spectrum of the ADA deficiency phenotype is largely related to the variability in genetic mutations. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– ADA deficiency typically leads to a severe combined immunodeficiency (SCID)  (<a class="graphic graphic_table graphicRef139920" href="/z/d/graphic/139920.html" rel="external">table 1</a>) that presents in the first few months of life, unless identified prior to onset of symptoms by newborn screening (NBS). However, there are also a few patients with a later onset and relatively milder disease. Typical signs and symptoms of SCID include failure to thrive, life-threatening infections, chronic mucocutaneous fungal infections, and/or opportunistic infections. Features that suggest ADA deficiency, but not most other forms of SCID, include earlier age of presentation with failure to thrive and noninfectious respiratory distress (often before four months of age), rib cage abnormalities, early neurologic abnormalities, and sensory-neural hearing loss. In late presenters, recurrent infection, opportunistic infections, and an unexplained lymphopenia may raise the suspicion of an unusual form of ADA deficiency. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– SCID is suspected when there is a positive NBS or the infant presents with typical features. Additional findings that aid in diagnosis of ADA deficiency include (see <a class="local">'Laboratory, radiographic, and histologic findings'</a> above and <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Absent ADA in lysed erythrocytes and elevated levels of adenosine and deoxyadenosine levels in the urine and plasma.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe T cell deficiency manifested by lymphopenia and poor T cell responses to mitogens and antigens; inability to mount specific antibody responses in most patients, but immunoglobulin levels are variable.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Absent thymic shadow on chest radiograph  (<a class="graphic graphic_diagnosticimage graphicRef119937" href="/z/d/graphic/119937.html" rel="external">image 1</a>). Additional radiographic abnormalities seen in ADA deficiency but not other forms of SCID include flaring of the anterior ribs and squaring or spurring of the inferolateral margin of the scapula  (<a class="graphic graphic_diagnosticimage graphicRef135224" href="/z/d/graphic/135224.html" rel="external">image 2</a>).</p><p></p><p class="bulletIndent1">The diagnosis is confirmed by identification of biallelic pathogenic variants in the <em>ADA1</em> gene.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of ADA deficiency includes all other forms of autosomal-recessive SCID, complete DiGeorge syndrome, and purine nucleoside phosphorylase deficiency. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H4178358855"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge Arye Rubinstein, MD, who contributed to earlier versions of this topic review.</p><p>The editorial staff at UpToDate also acknowledge E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sanchez JJ, Monaghan G, Børsting C, et al. Carrier frequency of a nonsense mutation in the adenosine deaminase (ADA) gene implies a high incidence of ADA-deficient severe combined immunodeficiency (SCID) in Somalia and a single, common haplotype indicates common ancestry. Ann Hum Genet 2007; 71:336.</a></li><li><a class="nounderline abstract_t">Hirschhorn R. Overview of biochemical abnormalities and molecular genetics of adenosine deaminase deficiency. Pediatr Res 1993; 33:S35.</a></li><li><a class="nounderline abstract_t">Buckley RH, Schiff RI, Schiff SE, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 1997; 130:378.</a></li><li><a class="nounderline abstract_t">Hershfield MS. Genotype is an important determinant of phenotype in adenosine deaminase deficiency. Curr Opin Immunol 2003; 15:571.</a></li><li><a class="nounderline abstract_t">Dvorak CC, Haddad E, Buckley RH, et al. The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). J Allergy Clin Immunol 2019; 143:405.</a></li><li><a class="nounderline abstract_t">Wiginton DA, Adrian GS, Friedman RL, et al. Cloning of cDNA sequences of human adenosine deaminase. Proc Natl Acad Sci U S A 1983; 80:7481.</a></li><li><a class="nounderline abstract_t">Wiginton DA, Kaplan DJ, States JC, et al. Complete sequence and structure of the gene for human adenosine deaminase. Biochemistry 1986; 25:8234.</a></li><li><a class="nounderline abstract_t">Jhanwar SC, Berkvens TM, Breukel C, et al. Localization of human adenosine deaminase (ADA) gene sequences to the q12----q13.11 region of chromosome 20 by in situ hybridization. Cytogenet Cell Genet 1989; 50:168.</a></li><li><a class="nounderline abstract_t">Markert ML, Norby-Slycord C, Ward FE. A high proportion of ADA point mutations associated with a specific alanine-to-valine substitution. Am J Hum Genet 1989; 45:354.</a></li><li><a class="nounderline abstract_t">Hirschhorn R, Tzall S, Ellenbogen A, Orkin SH. Identification of a point mutation resulting in a heat-labile adenosine deaminase (ADA) in two unrelated children with partial ADA deficiency. J Clin Invest 1989; 83:497.</a></li><li><a class="nounderline abstract_t">Hershfield MS, Kredich NM, Ownby DR, et al. In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine in adenosine deaminase-deficient patients. J Clin Invest 1979; 63:807.</a></li><li class="breakAll">Middleton's allergy: Principles and practice, 6th ed, Adkinson NF, Yunginger JW, Busse WW, et al (Eds), Mosby, St. Louis 2003.</li><li><a class="nounderline abstract_t">Rubinstein A, Hirschhorn R, Sicklick M, Murphy RA. In vivo and in vitro effects of thymosin and adenosine deaminase on adenosine-deaminase-deficient lymphocytes. N Engl J Med 1979; 300:387.</a></li><li><a class="nounderline abstract_t">Tsui M, Min W, Ng S, et al. The Use of Induced Pluripotent Stem Cells to Study the Effects of Adenosine Deaminase Deficiency on Human Neutrophil Development. Front Immunol 2021; 12:748519.</a></li><li><a class="nounderline abstract_t">Joachims ML, Marble PA, Laurent AB, et al. Restoration of adenosine deaminase-deficient human thymocyte development in vitro by inhibition of deoxynucleoside kinases. J Immunol 2008; 181:8153.</a></li><li><a class="nounderline abstract_t">Wakamiya M, Blackburn MR, Jurecic R, et al. Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice. Proc Natl Acad Sci U S A 1995; 92:3673.</a></li><li><a class="nounderline abstract_t">Blackburn MR, Datta SK, Kellems RE. Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem 1998; 273:5093.</a></li><li><a class="nounderline abstract_t">Apasov SG, Blackburn MR, Kellems RE, et al. Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling. J Clin Invest 2001; 108:131.</a></li><li><a class="nounderline abstract_t">Cassani B, Mirolo M, Cattaneo F, et al. Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. Blood 2008; 111:4209.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Simmonds HA, Fairbanks LD, et al. Adult onset immunodeficiency caused by inherited adenosine deaminase deficiency. J Immunol 1994; 153:2331.</a></li><li><a class="nounderline abstract_t">Arredondo-Vega FX, Santisteban I, Daniels S, et al. Adenosine deaminase deficiency: genotype-phenotype correlations based on expressed activity of 29 mutant alleles. Am J Hum Genet 1998; 63:1049.</a></li><li><a class="nounderline abstract_t">Lanfranchi A, Lougaris V, Notarangelo LD, et al. Maternal T-cell engraftment impedes with diagnosis of a SCID-ADA patient. Clin Immunol 2018; 193:118.</a></li><li><a class="nounderline abstract_t">Bollinger ME, Arredondo-Vega FX, Santisteban I, et al. Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency. N Engl J Med 1996; 334:1367.</a></li><li><a class="nounderline abstract_t">Roifman CM, Zhang J, Atkinson A, et al. Adenosine deaminase deficiency can present with features of Omenn syndrome. J Allergy Clin Immunol 2008; 121:1056.</a></li><li><a class="nounderline abstract_t">Morgan G, Levinsky RJ, Hugh-Jones K, et al. Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency. Clin Exp Immunol 1987; 70:491.</a></li><li><a class="nounderline abstract_t">Heyderman RS, Morgan G, Levinsky RJ, Strobel S. Successful bone marrow transplantation and treatment of BCG infection in two patients with severe combined immunodeficiency. Eur J Pediatr 1991; 150:477.</a></li><li><a class="nounderline abstract_t">Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010; 362:314.</a></li><li><a class="nounderline abstract_t">Hirschhorn R, Tzall S, Ellenbogen A. Hot spot mutations in adenosine deaminase deficiency. Proc Natl Acad Sci U S A 1990; 87:6171.</a></li><li><a class="nounderline abstract_t">Artac H, Göktürk B, Bozdemir SE, et al. Late-onset adenosine deaminase deficiency presenting with Heck's disease. Eur J Pediatr 2010; 169:1033.</a></li><li><a class="nounderline abstract_t">Ozsahin H, Arredondo-Vega FX, Santisteban I, et al. Adenosine deaminase deficiency in adults. Blood 1997; 89:2849.</a></li><li><a class="nounderline abstract_t">Sauer AV, Brigida I, Carriglio N, et al. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood 2012; 119:1428.</a></li><li><a class="nounderline abstract_t">Husain M, Grunebaum E, Naqvi A, et al. Burkitt's lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase. J Pediatr 2007; 151:93.</a></li><li><a class="nounderline abstract_t">Migliavacca M, Assanelli A, Ponzoni M, et al. First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature. Front Immunol 2018; 9:113.</a></li><li class="breakAll">Grunebaum E, Hospital for Sick Children, 2018, personal communication.</li><li><a class="nounderline abstract_t">Kesserwan C, Sokolic R, Cowen EW, et al. Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency. J Allergy Clin Immunol 2012; 129:762.</a></li><li><a class="nounderline abstract_t">Grunebaum E, Chung CT, Dadi H, et al. Purine metabolism, immune reconstitution, and abdominal adipose tumor after gene therapy for adenosine deaminase deficiency. J Allergy Clin Immunol 2011; 127:1417.</a></li><li><a class="nounderline abstract_t">Engel BC, Podsakoff GM, Ireland JL, et al. Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: a case report. Blood 2007; 109:503.</a></li><li><a class="nounderline abstract_t">Grunebaum E, Cutz E, Roifman CM. Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency. J Allergy Clin Immunol 2012; 129:1588.</a></li><li><a class="nounderline abstract_t">Dhanju R, Min W, Ackerley C, et al. Pulmonary alveolar proteinosis in adenosine deaminase-deficient mice. J Allergy Clin Immunol 2014; 133:1467.</a></li><li><a class="nounderline abstract_t">Litvack ML, Wigle TJ, Lee J, et al. Alveolar-like Stem Cell-derived Myb(-) Macrophages Promote Recovery and Survival in Airway Disease. Am J Respir Crit Care Med 2016; 193:1219.</a></li><li><a class="nounderline abstract_t">Scott O, Kim VH, Reid B, et al. Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience. J Clin Immunol 2017; 37:582.</a></li><li><a class="nounderline abstract_t">Komarow HD, Sokolic R, Hershfield MS, et al. Impulse oscillometry identifies peripheral airway dysfunction in children with adenosine deaminase deficiency. Orphanet J Rare Dis 2015; 10:159.</a></li><li><a class="nounderline abstract_t">Nofech-Mozes Y, Blaser SI, Kobayashi J, et al. Neurologic abnormalities in patients with adenosine deaminase deficiency. Pediatr Neurol 2007; 37:218.</a></li><li><a class="nounderline abstract_t">Hönig M, Albert MH, Schulz A, et al. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood 2007; 109:3595.</a></li><li><a class="nounderline abstract_t">Albuquerque W, Gaspar HB. Bilateral sensorineural deafness in adenosine deaminase-deficient severe combined immunodeficiency. J Pediatr 2004; 144:278.</a></li><li><a class="nounderline abstract_t">Kuo CY, Garabedian E, Puck J, et al. Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID) in the US Immunodeficiency Network (USIDNet) Registry. J Clin Immunol 2020; 40:1124.</a></li><li><a class="nounderline abstract_t">Sauer AV, Hernandez RJ, Fumagalli F, et al. Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients. Sci Rep 2017; 7:40136.</a></li><li><a class="nounderline abstract_t">Titman P, Pink E, Skucek E, et al. Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies. Blood 2008; 112:3907.</a></li><li><a class="nounderline abstract_t">Nikolajeva O, Worth A, Hague R, et al. Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome. J Clin Immunol 2015; 35:366.</a></li><li><a class="nounderline abstract_t">Pham-Huy A, Kim VHD, Nizalik E, et al. Atypical hemolytic-uremic syndrome in a patient with adenosine deaminase deficiency. LymphoSign J 2015; 2:195.</a></li><li><a class="nounderline abstract_t">Bogdał A, Badeński A, Pac M, et al. Atypical Hemolytic Uremic Syndrome (aHUS) and Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)-Two Diseases That Exacerbate Each Other: Case Report. Int J Mol Sci 2021; 22.</a></li><li><a class="nounderline abstract_t">Ratech H, Greco MA, Gallo G, et al. Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations. Am J Pathol 1985; 120:157.</a></li><li><a class="nounderline abstract_t">Pajno R, Pacillo L, Recupero S, et al. Urogenital Abnormalities in Adenosine Deaminase Deficiency. J Clin Immunol 2020; 40:610.</a></li><li><a class="nounderline abstract_t">Cohen A, Hirschhorn R, Horowitz SD, et al. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A 1978; 75:472.</a></li><li><a class="nounderline abstract_t">Donofrio J, Coleman MS, Hutton JJ, et al. Overproduction of adenine deoxynucleosides and deoxynucletides in adenosine deaminase deficiency with severe combined immunodeficiency disease. J Clin Invest 1978; 62:884.</a></li><li><a class="nounderline abstract_t">Simmonds HA, Sahota A, Potter CF, Cameron JS. Purine metabolism and immunodeficiency: urinary purine excretion as a diagnostic screening test in adenosine deaminase and purine nucleoside phosphorylase deficiency. Clin Sci Mol Med 1978; 54:579.</a></li><li><a class="nounderline abstract_t">Kim VH, Pham-Huy A, Grunebaum E. Neutropenia among patients with adenosine deaminase deficiency. J Allergy Clin Immunol 2019; 143:403.</a></li><li class="breakAll">Wolfson JJ, Cross VF. The radiologic findings in 49 patients with combined immunodeficiency. In: Combined immunodeficiency diseases and adenosine deaminase deficiency: A molecular defect, Meuwissen HJ, Pickering RJ, Pollara B, Porter IH (Eds), Academic Press, New York 1975. p.225.</li><li><a class="nounderline abstract_t">Manson D, Diamond L, Oudjhane K, et al. Characteristic scapular and rib changes on chest radiographs of children with ADA-deficiency SCIDS in the first year of life. Pediatr Radiol 2013; 43:589.</a></li><li><a class="nounderline abstract_t">Sauer AV, Mrak E, Hernandez RJ, et al. ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency. Blood 2009; 114:3216.</a></li><li><a class="nounderline abstract_t">Sokolic R, Maric I, Kesserwan C, et al. Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. Blood 2011; 118:2688.</a></li><li><a class="nounderline abstract_t">Ratech H, Hirschhorn R, Greco MA. Pathologic findings in adenosine deaminase deficient-severe combined immunodeficiency. II. Thymus, spleen, lymph node, and gastrointestinal tract lymphoid tissue alterations. Am J Pathol 1989; 135:1145.</a></li><li><a class="nounderline abstract_t">Morinishi Y, Imai K, Nakagawa N, et al. Identification of severe combined immunodeficiency by T-cell receptor excision circles quantification using neonatal guthrie cards. J Pediatr 2009; 155:829.</a></li><li><a class="nounderline abstract_t">Vogel BH, Bonagura V, Weinberg GA, et al. Newborn screening for SCID in New York State: experience from the first two years. J Clin Immunol 2014; 34:289.</a></li><li><a class="nounderline abstract_t">Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA 2014; 312:729.</a></li><li><a class="nounderline abstract_t">Routes JM, Grossman WJ, Verbsky J, et al. Statewide newborn screening for severe T-cell lymphopenia. JAMA 2009; 302:2465.</a></li><li><a class="nounderline abstract_t">Al-Dirbashi OY, Ogrel S, McIntosh N, et al. Tandem mass spectrometric determination of purine metabolites and adenosine deaminase activity for newborn screening of ADA-SCID. LymphoSign J 2015; 2:135.</a></li><li><a class="nounderline abstract_t">Argudo-Ramírez A, Martín-Nalda A, Marín-Soria JL, et al. First Universal Newborn Screening Program for Severe Combined Immunodeficiency in Europe. Two-Years' Experience in Catalonia (Spain). Front Immunol 2019; 10:2406.</a></li><li><a class="nounderline abstract_t">Azzari C, la Marca G, Resti M. Neonatal screening for severe combined immunodeficiency caused by an adenosine deaminase defect: a reliable and inexpensive method using tandem mass spectrometry. J Allergy Clin Immunol 2011; 127:1394.</a></li><li><a class="nounderline abstract_t">la Marca G, Canessa C, Giocaliere E, et al. Tandem mass spectrometry, but not T-cell receptor excision circle analysis, identifies newborns with late-onset adenosine deaminase deficiency. J Allergy Clin Immunol 2013; 131:1604.</a></li><li><a class="nounderline abstract_t">Pérignon JL, Durandy A, Peter MO, et al. Early prenatal diagnosis of inherited severe immunodeficiencies linked to enzyme deficiencies. J Pediatr 1987; 111:595.</a></li><li class="breakAll">Hershfield M. Adenosine deaminase deficiency. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2006 Oct 03 [updated 2009 Jul 14]. http://www.ncbi.nlm.nih.gov/pubmed?term=20301656 (Accessed on February 15, 2011).</li></ol></div><div id="topicVersionRevision">Topic 3907 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17181544" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Carrier frequency of a nonsense mutation in the adenosine deaminase (ADA) gene implies a high incidence of ADA-deficient severe combined immunodeficiency (SCID) in Somalia and a single, common haplotype indicates common ancestry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8433873" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Overview of biochemical abnormalities and molecular genetics of adenosine deaminase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9063412" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14499267" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Genotype is an important determinant of phenotype in adenosine deaminase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30193840" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6200875" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cloning of cDNA sequences of human adenosine deaminase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3028473" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Complete sequence and structure of the gene for human adenosine deaminase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2776485" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Localization of human adenosine deaminase (ADA) gene sequences to the q12----q13.11 region of chromosome 20 by in situ hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2773932" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A high proportion of ADA point mutations associated with a specific alanine-to-valine substitution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2783588" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Identification of a point mutation resulting in a heat-labile adenosine deaminase (ADA) in two unrelated children with partial ADA deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/312296" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine in adenosine deaminase-deficient patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/312296" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine in adenosine deaminase-deficient patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/310515" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : In vivo and in vitro effects of thymosin and adenosine deaminase on adenosine-deaminase-deficient lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34777360" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The Use of Induced Pluripotent Stem Cells to Study the Effects of Adenosine Deaminase Deficiency on Human Neutrophil Development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018008" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Restoration of adenosine deaminase-deficient human thymocyte development in vitro by inhibition of deoxynucleoside kinases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7731963" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9478961" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11435465" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18218852" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8051429" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Adult onset immunodeficiency caused by inherited adenosine deaminase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9758612" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Adenosine deaminase deficiency: genotype-phenotype correlations based on expressed activity of 29 mutant alleles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29355610" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Maternal T-cell engraftment impedes with diagnosis of a SCID-ADA patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8614422" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18243287" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Adenosine deaminase deficiency can present with features of Omenn syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3436096" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1915499" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Successful bone marrow transplantation and treatment of BCG infection in two patients with severe combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20107217" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Vaccine-acquired rotavirus in infants with severe combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2166947" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hot spot mutations in adenosine deaminase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20039061" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Late-onset adenosine deaminase deficiency presenting with Heck's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9108404" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Adenosine deaminase deficiency in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22184407" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17586199" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Burkitt's lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29456531" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29456531" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22153773" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21531016" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Purine metabolism, immune reconstitution, and abdominal adipose tumor after gene therapy for adenosine deaminase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16973956" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22409989" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24439080" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pulmonary alveolar proteinosis in adenosine deaminase-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26730942" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Alveolar-like Stem Cell-derived Myb(-) Macrophages Promote Recovery and Survival in Airway Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28748310" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26682746" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Impulse oscillometry identifies peripheral airway dysfunction in children with adenosine deaminase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17765813" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Neurologic abnormalities in patients with adenosine deaminase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17185467" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14760277" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Bilateral sensorineural deafness in adenosine deaminase-deficient severe combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32880085" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID) in the US Immunodeficiency Network (USIDNet) Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28074903" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18645040" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25875700" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Atypical hemolytic-uremic syndrome in a patient with adenosine deaminase deficiency</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34502390" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Atypical Hemolytic Uremic Syndrome (aHUS) and Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)-Two Diseases That Exacerbate Each Other: Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4014441" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32307643" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Urogenital Abnormalities in Adenosine Deaminase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/272665" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/308954" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Overproduction of adenine deoxynucleosides and deoxynucletides in adenosine deaminase deficiency with severe combined immunodeficiency disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/108044" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Purine metabolism and immunodeficiency: urinary purine excretion as a diagnostic screening test in adenosine deaminase and purine nucleoside phosphorylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29753815" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Neutropenia among patients with adenosine deaminase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29753815" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Neutropenia among patients with adenosine deaminase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23179487" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Characteristic scapular and rib changes on chest radiographs of children with ADA-deficiency SCIDS in the first year of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19633200" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21725047" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2596574" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pathologic findings in adenosine deaminase deficient-severe combined immunodeficiency. II. Thymus, spleen, lymph node, and gastrointestinal tract lymphoid tissue alterations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628217" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Identification of severe combined immunodeficiency by T-cell receptor excision circles quantification using neonatal guthrie cards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24578017" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Newborn screening for SCID in New York State: experience from the first two years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25138334" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996402" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Statewide newborn screening for severe T-cell lymphopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Tandem mass spectrometric determination of purine metabolites and adenosine deaminase activity for newborn screening of ADA-SCID</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31695692" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : First Universal Newborn Screening Program for Severe Combined Immunodeficiency in Europe. Two-Years' Experience in Catalonia (Spain).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21624616" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Neonatal screening for severe combined immunodeficiency caused by an adenosine deaminase defect: a reliable and inexpensive method using tandem mass spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23280131" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Tandem mass spectrometry, but not T-cell receptor excision circle analysis, identifies newborns with late-onset adenosine deaminase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3116192" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Early prenatal diagnosis of inherited severe immunodeficiencies linked to enzyme deficiencies.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
